Sisram Medical partners Fosun Wanbang for China distribution of botulinum toxin product

Sisram Medical Ltd announced on September 22, 2025, that its subsidiary, Sisram Tianjin, entered into a Commercial Distribution Co-operation Agreement with Fosun Wanbang (Jiangsu). Under the agreement, Sisram Tianjin will handle commercialization, marketing, and medical education for the Product, botulinum toxin type A for injection (DaxibotulinumtoxinA-lanm), in Mainland China. Fosun Wanbang (Jiangsu) will manage import, procurement, logistics, and channel distribution. The agreement is effective from September 22, 2025, to September 21, 2026, aiming to strengthen Sisram Medical’s market position and generate additional revenue.

Service fees paid by Fosun Wanbang (Jiangsu) to Sisram Tianjin will be calculated using a formula: Total Amount of Sales (excluding VAT) – Procurement Costs and Import Tax – Operating Costs – Other Expenses. Annual caps for the transaction are set at $17,000,000 for the period from September 22, 2025, to December 31, 2025, and $17,000,000 for January 1, 2026, to September 21, 2026. These caps are based on estimated sales volume, market prices, and fees for comparable services.

Fosun Wanbang (Jiangsu) is an indirect wholly-owned subsidiary of Fosun Pharma, Sisram Medical's controlling shareholder. This makes the agreement a continuing connected transaction under Listing Rules. The transaction exceeds 0.1% but is less than 5% of applicable percentage ratios, requiring reporting, annual review, and announcement.